Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
VNDA [NASD]
Vanda Pharmaceuticals Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E38.96 EPS (ttm)0.42 Insider Own3.40% Shs Outstand54.73M Perf Week3.27%
Market Cap908.15M Forward P/E15.51 EPS next Y1.06 Insider Trans-18.92% Shs Float53.10M Perf Month-3.52%
Income23.30M PEG- EPS next Q0.15 Inst Own- Short Float9.92% Perf Quarter19.74%
Sales248.20M P/S3.66 EPS this Y-79.90% Inst Trans1.41% Short Ratio9.25 Perf Half Y48.78%
Book/sh8.28 P/B1.99 EPS next Y76.67% ROA4.60% Target Price24.00 Perf Year42.71%
Cash/sh6.66 P/C2.47 EPS next 5Y- ROE5.40% 52W Range9.00 - 20.51 Perf YTD25.11%
Dividend- P/FCF18.16 EPS past 5Y19.60% ROI4.20% 52W High-19.21% Beta0.47
Dividend %- Quick Ratio6.20 Sales past 5Y17.70% Gross Margin90.60% 52W Low84.11% ATR0.61
Employees292 Current Ratio6.20 Sales Q/Q11.20% Oper. Margin11.00% RSI (14)51.49 Volatility3.25% 3.95%
OptionableYes Debt/Eq0.00 EPS Q/Q92.10% Profit Margin9.40% Rel Volume0.38 Prev Close16.44
ShortableYes LT Debt/Eq0.00 EarningsFeb 10 AMC Payout0.00% Avg Volume569.19K Price16.57
Recom1.00 SMA203.39% SMA50-3.36% SMA20026.25% Volume206,469 Change0.79%
Jan-14-21Downgrade Citigroup Buy → Neutral $14
Oct-29-20Upgrade Citigroup Neutral → Buy $14
Jun-09-20Downgrade Citigroup Buy → Neutral $14
Mar-16-20Downgrade Oppenheimer Perform → Underperform
Mar-12-20Upgrade Citigroup Neutral → Buy $14
Nov-07-19Downgrade Citigroup Buy → Neutral $19
Aug-01-19Upgrade Citigroup Neutral → Buy $19
Jul-25-19Downgrade Stifel Buy → Hold $26 → $17
Dec-11-18Downgrade Oppenheimer Outperform → Perform
Dec-04-18Upgrade Cantor Fitzgerald Neutral → Overweight
Dec-04-18Reiterated Jefferies Buy $30 → $40
Nov-08-18Resumed Jefferies Buy
Sep-21-18Resumed Oppenheimer Outperform
May-23-18Initiated Citigroup Buy $26
Jan-19-18Initiated Seaport Global Securities Buy $20
Sep-14-17Reiterated Piper Jaffray Overweight $23 → $26
Jun-27-17Resumed Piper Jaffray Overweight $23
May-26-17Initiated H.C. Wainwright Buy $18
Apr-12-17Initiated Oppenheimer Outperform $21
Nov-09-16Initiated Aegis Capital Buy $24
Apr-16-21 10:50PM  
VANDA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Vanda Pharmaceuticals Inc. - VNDA
PR Newswire
02:33PM  
Lifshitz Law Firm, P.C. Announces Investigations of Inovio Pharmaceuticals, Inc. (NasdaqGS: INO), Merit Medical Systems, Inc. (NasdaqGS: MMSI), RCI Hospitality Holdings, Inc. (NasdaqGM: RICK), and Vanda Pharmaceuticals, Inc. (NasdaqGS: VNDA)
GlobeNewswire
Apr-13-21 08:15AM  
Update in Lawsuit for Investors in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Announced by Shareholders Foundation
ACCESSWIRE
Apr-06-21 06:40AM  
With Sales Expected To Rise, Vanda Pharmaceuticals Stock Could Surge
TipRanks
Mar-23-21 07:15AM  
NASDAQ: VNDA Investor Notice: Update in Lawsuit against Vanda Pharmaceuticals Inc. announced by Shareholders Foundation
GlobeNewswire -6.64%
Mar-18-21 04:26PM  
Shuman, Glenn & Stecker Investigates Vanda Pharmaceuticals Inc.
Business Wire
09:11AM  
Return On Capital Employed Overview: Vanda Pharmaceuticals
Benzinga
Mar-17-21 01:56PM  
SHAREHOLDER ALERT: Barr Law Group Investigating VNDA, VLDR, RIDE, and ABT; Shareholders are Encouraged to Contact the Firm
GlobeNewswire
Mar-12-21 10:50PM  
VANDA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Vanda Pharmaceuticals Inc. - VNDA
Business Wire
Mar-11-21 01:52PM  
Shareholder Alert: Robbins LLP Announces that Vanda Pharmaceuticals Inc. (VNDA) Class Action Survives Motion to Dismiss
Business Wire
Feb-23-21 02:49PM  
Pacira Pharmaceuticals Getting Closer To Key Technical Measure
Investor's Business Daily
Feb-14-21 01:32PM  
15 Best Small-Cap Healthcare Stocks to Buy
Insider Monkey
Feb-12-21 12:54AM  
Vanda Pharmaceuticals Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Simply Wall St.
Feb-11-21 10:28AM  
Return On Capital Employed Overview: Vanda Pharmaceuticals
Benzinga +21.16%
Feb-10-21 08:30PM  
Vanda Pharmaceuticals Inc (VNDA) Q4 2020 Earnings Call Transcript
Motley Fool
04:28PM  
Recap: Vanda Pharmaceuticals Q4 Earnings
Benzinga
04:01PM  
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
PR Newswire
07:34AM  
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs
Benzinga
Feb-02-21 04:30PM  
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 10, 2021
PR Newswire
Dec-19-20 06:11PM  
Is VNDA A Good Stock To Buy Now According To Hedge Funds?
Insider Monkey
Dec-02-20 03:02PM  
Here's Why Vanda Pharmaceuticals Jumped Higher Today
Motley Fool +9.32%
07:35AM  
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod
Benzinga
Dec-01-20 06:00PM  
FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome
PR Newswire
04:47AM  
Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Stock Is Going Strong: Have Financials A Role To Play?
Simply Wall St.
Nov-17-20 12:43PM  
Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed
Zacks
Oct-29-20 09:31AM  
Benzinga's Top Upgrades, Downgrades For October 29, 2020
Benzinga +8.97%
Oct-28-20 05:55PM  
Vanda Pharmaceuticals (VNDA) Q3 Earnings Surpass Estimates
Zacks
04:01PM  
Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results
PR Newswire
02:30PM  
Vanda Pharmaceuticals, Inc. to Host Earnings Call
ACCESSWIRE
Oct-26-20 04:01PM  
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis
PR Newswire
Oct-21-20 04:45PM  
Vanda Pharmaceuticals to Announce Third Quarter 2020 Financial Results on October 28, 2020
PR Newswire
Oct-13-20 01:14PM  
Vanda Pharmaceuticals Inc. (VNDA): Hedge Funds Taking Some Chips Off The Table
Insider Monkey
Oct-02-20 01:44PM  
How Does Vanda Pharmaceuticals' (NASDAQ:VNDA) CEO Pay Compare With Company Performance?
Simply Wall St.
Sep-15-20 03:41PM  
Top Biotech Stocks for Q4 2020
Investopedia
Aug-31-20 06:30PM  
Vanda Pharmaceuticals Provides Update on Tradipitant Development Program
PR Newswire
Aug-18-20 10:24AM  
Would Shareholders Who Purchased Vanda Pharmaceuticals'(NASDAQ:VNDA) Stock Three Years Be Happy With The Share price Today?
Simply Wall St. -8.20%
07:00AM  
Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia
PR Newswire
Aug-06-20 08:21PM  
Oil Down But OPEC+ Member Cuts Cap Losses
Investing.com
Aug-05-20 06:05PM  
Vanda Pharmaceuticals (VNDA) Q2 Earnings Surpass Estimates
Zacks
04:01PM  
Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results
PR Newswire
Aug-03-20 08:53AM  
Were Hedge Funds Right About Vanda Pharmaceuticals Inc. (VNDA)?
Insider Monkey
07:00AM  
FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome
PR Newswire
Jul-29-20 05:00PM  
Vanda Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
PR Newswire
Jul-22-20 12:32PM  
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
Zacks
Jul-21-20 04:04PM  
Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Vanda Pharmaceuticals Inc. (VNDA)
Business Wire
Jul-14-20 11:02AM  
FDA Grants Extra Access to Vanda's Tradipitant to a Patient
Zacks
08:04AM  
The Daily Biotech Pulse: Blueprint, Roche Ink $1.7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits
Benzinga
Jul-13-20 04:30PM  
FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis
PR Newswire
Jun-19-20 02:38PM  
Vanda Pharmaceuticals Inc. (VNDA): Hedge Funds Sticking Around
Insider Monkey
May-26-20 07:00AM  
Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting
PR Newswire
May-21-20 05:08PM  
U.S. doctors call for remdesivir data to guide coronavirus treatment
Reuters
May-20-20 05:20PM  
Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit
PR Newswire +6.73%
10:45AM  
Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir
PR Newswire
May-15-20 11:43AM  
1 Pharma Stock to Avoid at All Costs
Motley Fool
May-14-20 07:03AM  
This Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19
Motley Fool
May-13-20 07:00AM  
Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome
PR Newswire
May-08-20 07:32PM  
Edited Transcript of VNDA earnings conference call or presentation 6-May-20 8:30pm GMT
Thomson Reuters StreetEvents
May-07-20 11:31AM  
Vanda Pharmaceuticals (VNDA) Q1 2020 Earnings Call Transcript
Motley Fool
May-06-20 06:45PM  
Vanda Pharmaceuticals (VNDA) Meets Q1 Earnings Estimates
Zacks
Apr-29-20 04:05PM  
Vanda Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 6, 2020
PR Newswire
12:34PM  
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
Zacks
Apr-27-20 02:18PM  
What Is Vanda Pharmaceuticals's (NASDAQ:VNDA) P/E Ratio After Its Share Price Rocketed?
Simply Wall St.
Apr-23-20 09:12AM  
Another 140,000 apply for unemployment benefits in D.C., Md. and Va.
American City Business Journals
Apr-22-20 01:01PM  
Is Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) CEO Paid At A Competitive Rate?
Simply Wall St.
Apr-21-20 05:14PM  
This company gets FDA green light to proceed with study on possible COVID-19 treatment
Yahoo Finance Video
Apr-17-20 10:00AM  
Company News for Apr 17, 2020
Zacks
08:54AM  
Northam requests more federal aid, Montgomery County steps up PPE funding
American City Business Journals
Apr-16-20 10:58AM  
Vanda Begins Enrollment in Study for Severe Coronavirus Infection
Zacks +6.91%
08:09AM  
The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant
Benzinga
Apr-15-20 04:15PM  
Vanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in COVID-19 Infections in Collaboration With University of Washington Medicine
PR Newswire -7.79%
04:05PM  
Vanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia
PR Newswire
Apr-09-20 07:52AM  
The Daily Biotech Pulse: FDA Nod For Pfizer, Vanda Forges Partnership For COVID-19 Drug Research, Neuronetics Pre-Announces Revenue Shortfall
Benzinga
Apr-08-20 04:05PM  
Vanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against COVID-19
PR Newswire
Apr-03-20 02:26PM  
These D.C.-area biotech companies are making progress on COVID-19. Heres the latest.
American City Business Journals -6.81%
Apr-02-20 01:36PM  
Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia
PR Newswire +14.08%
Mar-19-20 12:59PM  
Vanda Pharmaceuticals hits another snag with FDA
American City Business Journals +9.47%
Mar-10-20 05:13PM  
Edited Transcript of VNDA earnings conference call or presentation 25-Feb-20 9:30pm GMT
Thomson Reuters StreetEvents +8.69%
Feb-27-20 05:35PM  
Vanda Pharmaceuticals Announces Participation at March 2020 Investor Conferences
PR Newswire
Feb-26-20 03:05PM  
Vandas latest study failed. But revenue grew in 2019.
American City Business Journals
Feb-25-20 04:13PM  
Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis
PR Newswire
04:01PM  
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
PR Newswire
Feb-21-20 12:26PM  
Should We Be Delighted With Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) ROE Of 30%?
Simply Wall St. -9.13%
Feb-19-20 07:00AM  
Vanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors
PR Newswire
Feb-18-20 08:22PM  
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
PR Newswire +5.28%
Feb-05-20 09:15AM  
Vertex (VRTX) Hits 52-Week High, Can the Run Continue?
Zacks
Feb-03-20 03:28PM  
Court rules against Vanda, in favor of FDA on clinical trials suit
American City Business Journals
Jan-31-20 06:24PM  
Vanda Pharmaceuticals Comments on Court Ruling
PR Newswire
Jan-16-20 02:57PM  
Vandas patent challenge over its schizophrenia drug is finally over. But it's not their only generics threat.
American City Business Journals
Jan-13-20 02:11PM  
Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt®
PR Newswire -5.61%
Jan-12-20 03:34PM  
3 Small Caps to Consider for Growth
GuruFocus.com
Dec-29-19 09:40PM  
Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus
Benzinga
Dec-23-19 02:27PM  
Do Vanda Pharmaceuticals's (NASDAQ:VNDA) Earnings Warrant Your Attention?
Simply Wall St.
Dec-12-19 05:15PM  
Mihael H. Polymeropoulos, MD, President and CEO of Vanda Pharmaceuticals Inc., to Receive The Physicians Committee for Responsible Medicine Trailblazer Award
PR Newswire
Dec-10-19 09:12PM  
Vanda Pharmaceuticals Inc. (VNDA): Hedge Funds In Wait-and-See Mode
Insider Monkey
Nov-19-19 07:15AM  
Edited Transcript of VNDA earnings conference call or presentation 6-Nov-19 9:30pm GMT
Thomson Reuters StreetEvents
Nov-18-19 04:01PM  
Vanda Pharmaceuticals Announces Participation at November 2019 Investor Conferences
PR Newswire
10:04AM  
These Stocks Could Bounce High in January and Beyond
GuruFocus.com
Nov-14-19 10:35AM  
Top Ranked Value Stocks to Buy for November 14th
Zacks
Nov-07-19 07:18AM  
The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs
Benzinga +10.58%
Nov-06-19 04:01PM  
Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results
PR Newswire
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jones Aranthan IIChief Corp. Affairs OfficerMar 15Option Exercise11.3215,000169,800111,935Mar 16 04:20 PM
Jones Aranthan IIChief Corp. Affairs OfficerMar 15Sale17.7218,000319,01093,935Mar 16 04:20 PM
Polymeropoulos Mihael HristosPresident and CEOMar 08Sale18.00175,0003,150,0521,221,062Mar 09 05:15 PM
Williams TimothySVP & General CounselMar 05Sale17.855,60099,96686,926Mar 08 05:47 PM
Birznieks GuntherSVP, Business DevelopmentMar 02Sale18.1916,620302,273171,708Mar 03 06:39 PM
Williams TimothySVP & General CounselMar 02Sale18.547,674142,30792,526Mar 03 06:43 PM
Jones Aranthan IIChief Corp. Affairs OfficerMar 02Sale18.043,86569,71796,935Mar 03 06:40 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 02Sale18.236,044110,191101,426Mar 03 06:40 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerMar 02Sale18.453,88871,72978,202Mar 03 06:42 PM
Polymeropoulos Mihael HristosPresident and CEOMar 02Sale18.3415,206278,9021,396,062Mar 03 06:41 PM
Polymeropoulos Mihael HristosPresident and CEOMar 01Sale18.457,479138,0031,411,268Mar 03 06:41 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 01Sale18.573,32761,780107,470Mar 03 06:40 PM
Williams TimothySVP & General CounselMar 01Sale18.6011,856220,543100,200Mar 03 06:43 PM
Birznieks GuntherSVP, Business DevelopmentMar 01Sale18.663,84571,744188,328Mar 03 06:39 PM
Jones Aranthan IIChief Corp. Affairs OfficerFeb 24Option Exercise12.2722,499276,063123,786Feb 26 05:17 PM
Jones Aranthan IIChief Corp. Affairs OfficerFeb 24Sale20.0122,986460,033100,800Feb 26 05:17 PM
DUGAN RICHARD WDirectorFeb 16Option Exercise7.1115,000106,65060,641Feb 18 08:43 PM
Watkins ThomasDirectorFeb 16Option Exercise7.1115,000106,65055,323Feb 18 08:43 PM
Watkins ThomasDirectorFeb 16Sale18.545,818107,85649,505Feb 18 08:43 PM
DUGAN RICHARD WDirectorFeb 16Sale18.545,754106,66354,887Feb 18 08:43 PM
Polymeropoulos Mihael HristosPresident and CEODec 15Option Exercise8.7546,663408,3011,342,897Dec 15 04:24 PM
Polymeropoulos Mihael HristosPresident and CEODec 15Sale13.0039,150508,8441,303,747Dec 15 04:24 PM
Polymeropoulos Mihael HristosPresident and CEODec 14Option Exercise8.7561,520538,3001,347,283Dec 15 04:24 PM
Polymeropoulos Mihael HristosPresident and CEODec 14Sale13.1951,049673,3061,296,234Dec 15 04:24 PM
Polymeropoulos Mihael HristosPresident and CEODec 11Option Exercise8.7541,817365,8991,320,816Dec 15 04:24 PM
Polymeropoulos Mihael HristosPresident and CEODec 11Sale12.8835,053451,3601,285,763Dec 15 04:24 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerAug 20Sale11.083,71041,10956,290Aug 21 06:08 PM
Williams TimothySVP & General CounselAug 14Sale11.813,68443,52679,356Aug 17 04:42 PM
Jones Aranthan IIChief Corp. Affairs OfficerAug 12Sale11.817,20085,01875,487Aug 14 04:39 PM
Jones Aranthan IIChief Corp. Affairs OfficerJul 27Sale10.627,31377,63182,687Jul 29 08:17 PM
Watkins ThomasDirectorMay 29Option Exercise7.3815,000110,70045,000Jun 02 04:13 PM
Watkins ThomasDirectorMay 29Sale11.509,677111,28635,323Jun 02 04:13 PM
DUGAN RICHARD WDirectorMay 28Option Exercise7.3815,000110,70050,770May 29 04:10 PM
DUGAN RICHARD WDirectorMay 28Sale11.0410,129111,80640,641May 29 04:10 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.